Eli Lilly’s (LLY) new weight loss pill is still in clinical trials and has not yet been approved by regulators. But that hasn ...

Eli Lilly is betting big on its experimental oral weight-loss drug even before reporting data from its late-stage trial by ...

Eli Lilly Chief Scientific Officer Dan Skovronsky spoke to CNBC about obesity pills and more on the future of weight loss.

Eli Lilly's Chief Scientific Officer Dan Skovronsky says the company wants to take big swings in Alzheimer's, ALS, chronic ...

About a dozen drugmakers are developing new weight-loss treatments aimed at preserving muscle, and industry analysts, ...

About a dozen drugmakers are developing new weight-loss treatments aimed at preserving muscle, and industry analysts, ...

A telehealth company partnered with a pharmacy that lacked a required license, raising doubts about the safety and efficacy ...

For years, conventional wisdom has been that weight loss is a matter of willpower. Those who are overweight or obese just need to try harder to eat less and exercise more. But while diet and ...

Experts noted that rapid and extreme weight loss can introduce unique risks, such as a weakened immune system and malnourishment, as well as potentially too much muscle loss. They’re also concerned ...

Eli Lilly and is strengthening its position in the lucrative weight management sector through a significant $2 billion acquisition of Versanis Bio. This strategic move centers on Bimagrumab, a ...

The FDA has said it has agreed to reconsider its decision to prevent compounding pharmacies from producing and selling versions of Eli ... weight-loss drugs, with Novo Nordisk and Lilly both ...

New data from Novo Nordisk’s phase 3 trial of an oral, high-dose formulation of semaglutide reinforces its potential as a weight-loss therapy in obesity, but Eli ... with Lilly’s drug was ...